New psoriasis drug could rival stelara in major trial

NCT ID NCT05335356

Completed Disease control Sponsor: Biocon Biologics UK Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested whether Bmab 1200, a biosimilar of the drug Stelara, works as well as Stelara for people with moderate to severe plaque psoriasis. 384 adults received either Bmab 1200 or Stelara over 40 weeks. The main goal was to see how much psoriasis symptoms improved after 12 weeks. If Bmab 1200 proves similar in effectiveness and safety, it could become a new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bmab 1200 (a biosimilar of Stelara, a biologic drug)
What this could lead to: If successful, Bmab 1200 could offer a more affordable or equally effective alternative to Stelara for controlling moderate to severe plaque psoriasis.
What could go wrong: This is a comparison study, not a test of a new mechanism. Even if Bmab 1200 works, it may not be superior to Stelara, and long-term safety is still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Contacts and locations

Locations

Apex Clinical Research Center

Mayfield Heights, Ohio, 44124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.